Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Return on Sales (2016 - 2025)

Historic Return on Sales for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to 0.14%.

  • Protalix BioTherapeutics' Return on Sales fell 400.0% to 0.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.09%, marking a year-over-year increase of 3000.0%. This contributed to the annual value of 0.05% for FY2024, which is 200.0% down from last year.
  • Latest data reveals that Protalix BioTherapeutics reported Return on Sales of 0.14% as of Q3 2025, which was down 400.0% from 0.01% recorded in Q2 2025.
  • Protalix BioTherapeutics' 5-year Return on Sales high stood at 0.46% for Q2 2023, and its period low was 1.77% during Q2 2021.
  • Moreover, its 5-year median value for Return on Sales was 0.33% (2023), whereas its average is 0.34%.
  • In the last 5 years, Protalix BioTherapeutics' Return on Sales crashed by -13900bps in 2021 and then surged by 11600bps in 2022.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Return on Sales stood at 0.77% in 2021, then surged by 52bps to 0.37% in 2022, then tumbled by -55bps to 0.58% in 2023, then surged by 162bps to 0.36% in 2024, then plummeted by -62bps to 0.14% in 2025.
  • Its Return on Sales stands at 0.14% for Q3 2025, versus 0.01% for Q2 2025 and 0.36% for Q1 2025.